Quantification of the whole-body distribution of PET radiopharmaceuticals, applied to 3-N-([18F]fluoroethyl)spiperone

Herzog, Hans; Coenen, Heinz H.; Kuwert, Torsten; Langen, Karl‐Josef; Feinendegen, L. E.

doi:10.1007/bf01465913

Cited by 15 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The combination of advanced technology and biological tracers has generated new pathophysiological data, and it has been shown that the application of bioOffprint requests to: A. van Lingen logical tracers might benefit larger groups of patients (Camici et al 1986;Tillisch et al 1986;Di Chiro et al 1987;Strauss 1990). Therefore, it is attractive to image these tracers in the body with the generally available equipment, as has been reported by Hoeflin et al (1989), Herzog et al (1990) and Paul (1987).…”

Section: Introductionmentioning

confidence: 99%

Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera

et al. 1992

View full text Add to dashboard Cite

Line-source experiments were conducted to assess the performance of a gamma-camera equipped with a specially designed 511-keV collimator for the planar imaging of positron emitters. The results were compared with the camera performance with routinely used collimators and radionuclides (thallium-201, technetium-99m and gallium-67). With positron emitters, scatter contributed less to the widening of the line spread function than with radionuclides emitting lower photon energies. These observations can be explained by the relative deterioration in the discrimination power of the gamma-camera to reject scattered radiation at low energies. Planar 511-keV imaging may provide relevant clinical information, as we showed by fluorodeoxyglucose studies in a patient with a myocardial infarction and in a patient with a malignant lymphoma. It is concluded that positron emitters can be effectively applied for planar imaging with the generally available gamma-cameras. This study implies that radiotracers developed for positron emission tomography may find a place in the practice of conventional nuclear medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera

et al. 1992

View full text Add to dashboard Cite

show abstract

“…Therefore, the abdomen will be difficult to evaluate with these tracers (Herzog et al 1990). Further reviews of the D2R reporter gene are to be found in previous publications (Herschman 2004a(Herschman , 2004b.…”

Section: Dopamine 2 Receptor (Hd2r)mentioning

confidence: 98%

Molecular Imaging of PET Reporter Gene Expression

Min

Gambhir²

2008

Molecular Imaging II

View full text Add to dashboard Cite

Multimodality molecular imaging continues to rapidly expand and is impacting many areas of biomedical research as well as patient management. Reporter-gene assays have emerged as a very general strategy for indirectly monitoring various intracellular events. Furthermore, reporter genes are being used to monitor gene/cell therapies, including the location(s), time variation, and magnitude of gene expression. This chapter reviews reporter gene technology and its major pre-clinical and clinical applications to date. The future appears quite promising for the continued expansion of the use of reporter genes in many evolving biomedically related arenas.

show abstract

“…An example of an acquisition scheme which was performed for the 18 F-labelled D2-receptor ligand [ 18 F]-fluoro-ethyl-spiperone is shown in Fig. 3 [8].…”

Section: Biodistribution Measurement Of Positron Emittersmentioning

confidence: 99%

Dosimetry related to SPECT and PET applications

Herzog

2001

Radiochimica Acta

Self Cite

View full text Add to dashboard Cite

Dosimetry / Radiation dose / Biodistribution / MIRD / Single photon emission computerized tomography / Positron emission tomographySummary. Nuclear medicine methods permit the in vivo measurement of physiological and metabolic functions. For this purpose metabolically active molecules are labelled with radionuclides. After the injection, these radiopharmaceuticals can be detected from outside the body with appropriate detectors such as conventional gamma cameras, single photon emission computerized tomographs (SPECT), or positron emission tomographs (PET). As with any application of ionizing radiation the benefits of nuclear medicine (the diagnosis and treatment of disease) must be balanced against the risks of the procedures. Risks in nuclear medicine are evaluated through dosimetry, the calculation of the radiation dose estimates, in which the energy deposited by the radiation in human tissues is quantitated. The first step of dosimetry is the determination of the biodistribution, i.e. the spatial and temporal distribution of the radiopharmaceutical within the body. When a new radiopharmaceutical is introduced such data are first derived from ex vivo experiments in animals. Further evaluations of the biokinetics and dosimetry are carried out via quantitative measurements in humans using the nuclear medicine imaging equipment, applying whole-body planar and tomographic methods. Based on the knowledge of the biodistribution and using the framework introduced by the MIRD committee as well as by the ICRP, the radiation dose to single organs and to the total body can be calculated. The purpose of this paper is to review methods for measuring radiopharmaceutical biodistributions in humans and for calculating the appropriate radiation dose quantities.

show abstract

Quantification of the whole-body distribution of PET radiopharmaceuticals, applied to 3-N-([18F]fluoroethyl)spiperone

Cited by 15 publications

References 13 publications

Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera

Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera

Molecular Imaging of PET Reporter Gene Expression

Dosimetry related to SPECT and PET applications

Contact Info

Product

Resources

About